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The effects of naringin (4’,5,7-trihydroxy flavonone-7-rhamnoglucoside), a flavonoid isolated from 
the grapefruit and other citrus fruit species were investigated on diabetic ketoacidosis (DKA) in a 
type 1 diabetic rat model. DKA is an acute life threatening complication of diabetes mellitus. Male 
Sprague-Dawley rats (225-250g) were divided into 5 groups (n=7). Group 1 (control) was treated 
daily with 1.0 ml/kg distilled water while group 2 was treated with 50 mg/kg of naringin, via gastric 
gavage respectively. Diabetes was induced in groups 3, 4 and 5 by a single intraperitoneal injection 
of 60 mg/kg streptozotocin in 0.1 M citrate buffer and was confirmed after 48 hours. Group 3 was 
further treated with subcutaneous insulin (4 IU/kg) twice daily respectively. Blood samples for 
analysis were collected by cardiac puncture. The animals were handled humanely according to the 
guidelines of the Animal Ethics Committee, University of KwaZulu Natal, number 106/13/Animal. 
The untreated diabetic rats (group 5) showed significant (p<0.0001) hyperglycemia, polydipsia, 
polyuria, weight loss, impaired glucose tolerance, low fasting plasma insulin (FPI) and low glycogen 
levels compared to the normal control. They also showed significantly (p<0.0001) elevated 
acetoacetate (AcAc), β-hydroxybutyrate (3HB), total ketone body (TKB), anion gap (AG) and 
potassium (p<0.05) levels compared to normal control. Furthermore, significant (p<0.01) reductions 
blood pH, sodium, chloride and bicarbonate (p<0.0001) levels were recorded compared to the normal 
control. Treatment of the diabetic groups with naringin did not improve fasting blood glucose and 
serum electrolyte levels but significantly improved weight loss (p<0.0001), water consumption 
(p<0.0001), hepatic glycogen level (p<0.05), 3HB (p<0.05), AcAc (p<0.05), TKB (p<0.01), 
bicarbonate (p<0.01), blood pH (p<0.01) and AG (p<0.05) compared to the diabetic control group.  
The results in this study therefore suggest that naringin reverses ketoacidosis but does not improve 
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1.1 Background on Diabetes mellitus (DM) 
Diabetes Mellitus (DM) is a global health problem with major public health, social and economic 
implications. It affects millions of people around the world. The International Diabetes 
Federation (IDF) global estimates indicate that the number of diabetics will increase from 382 
million recorded in 2013 to about 592 million by 2035 [1]. The greatest increases in prevalence 
are expected to occur in developing countries [2] especially in Africa where the number is 
expected to rise from about 19.8 million in 2013 to about 41.4 million by 2035 [1]. It is currently 
estimated that out of these numbers, 2.6 million are in South Africa, excluding undiagnosed 
cases estimated to be 63%) [1]. Thus, the true incidence and impact of diabetes in the region 
remains largely unknown as the available data could be an underestimation. As a result of the 
increasing prevalence and incidence of diabetes, a rise in complications leading to increased 
morbidity and mortality is expected. These include dysfunction, damage and failure of organs 
and systems such as eyes, nerves, kidney, blood vessels and heart. Eventually, this will have 
devastating social and economic effects in the region as the most productive members of the 
society; mostly breadwinners [3] are affected.  
1.1.1 Definition and classification of diabetes mellitus 
Diabetes mellitus (DM) is defined as a metabolic disorder of multiple aetiology characterised by 
chronic hyperglycaemia resulting from disturbances in carbohydrate, fat and protein metabolism 




features such as polyuria (frequent urination), polydipsia (frequent thirst) and polyphagia 
(frequent hunger). It is classified into 2 major types, type 1 and type 2 DM.  
Type 1 DM results from the autoimmune destruction of the insulin producing pancreatic beta (β) 
islet cells [6-8]. The auto antibodies progressively infiltrate the β-islet cells leading to an auto 
immune cellular mediated destruction. Consequently, the damaged β-cells cannot produce insulin 
and an absolute deficiency ensues. As a result, lifelong insulin replacement therapy cannot be 
circumvented. Recent statistics indicate that about 5-10% of people with diabetes have type 1 
DM [8] Also referred to as juvenile diabetes, type 1 DM mostly affects children and young 
adults generally occurring before the age of 40 years [9]. Studies have linked genetic 
predisposition to the development of type 1 DM with key predisposing factors being human 
leukocyte antigen (HLA) haplotypes DR4-DQ8 and DR3-DQ2 frequently encountered in 
children [7] while the protective HLA DR15-DQ6 haplotype, is a rare combination [10]. 
However, environmental factors have also been identified as possible trigger factors [11].  
Type 2 DM accounts for approximately 90-95% of the patients with diabetes [8]. In Africa too, 
specifically in the Sub-Saharan region, it is also the most common with trends showing increases 
in prevalence [3]. Among factors attributed to this rapid rise in prevalence include acquired 
sedentary lifestyles, dietary changes, population ageing, urbanization, poverty and the double 
burden of communicable diseases like HIV/ AIDS [3], tuberculosis and malaria especially in Sub 
Saharan Africa [12], a region ravaged by poverty with little to spare for healthcare funding. Type 
2 DM occurs as a result of insulin resistance and abnormalities in insulin secretion [13]. Insulin 
resistance is the inability of target tissues to increase glucose uptake in response to increased 
insulin levels. Chronic hyperglycemia in the β-cell results in increased sensitivity to glucose, 




depletion of insulin stores [14]. A majority of the people with type 2 DM are obese, with central 
visceral adiposity a key feature of the metabolic syndrome also characterized by atherogenic 
dyslipidemia, a pro-thrombotic state, a pro-inflammatory state and hypertension [14, 15]. 
1.1.2 Regulation of blood glucose homeostasis 
Insulin, a polypeptide hormone [16, 17] is secreted by the endocrine pancreatic beta (β) islet cells 
of Langerhans [18] and is involved in the regulation of glucose homeostasis. The pancreatic islet 
of Langerhans is also made up of the alpha (α), delta (δ) and pancreatic polypeptide (PP) cells 
which secrete glucagon, somatostatin and pancreatic polypeptide hormones, respectively [18]. 
Insulin is secreted primarily in response to glucose although other nutrients such as free fatty 
acids (FFA) and amino acids can augment its secretion [17]. Its main role is to maintain glucose 
homeostasis by stimulating the uptake, utilization and storage of glucose in muscle and adipose 
tissue while inhibiting hepatic production.  
The cellular uptake of glucose is mediated by transporters as the lipid bi-layers are impermeable 
to the carbohydrates. These include a family of facilitative glucose transporters (GLUT) which 
facilitate a uni-directional and energy independent process and a sodium glucose linked 
transporter (SGLT) which is an energy dependent process. The SGLTs are mainly limited to the 
kidney, skeletal muscle and intestines while the GLUTs are widely distributed but exhibit 
differences in substrate and tissue specificity. Among the GLUT isoforms identified include 






Glucose transporter Tissue distribution 
Glut 1 Ubiquitous distribution in tissues and culture 
cells. 
 Glut 2 Liver, pancreatic β-islets, kidney, small 
intestine.  
Glut 3 Brain and nerve cells. 
Glut 4 Insulin responsive tissues like adipose, skeletal 
and heart muscles. 
 
Table 1.1 Isoforms of glucose transporter molecules (GLUT) [19]. 
However, of all these GLUTs, only isoform 4 exhibits insulin sensitivity. GLUT-4, a trans-
membrane protein is exclusively expressed in the peripheral insulin sensitive tissues, fat and 
muscle tissues [20]. In the absence of insulin, it is sequestered in intracellular vesicles but on 
stimulation, it is translocated to the plasma membrane where it mediates glucose uptake [20]. 
The rest translocate glucose in an insulin independent manner.  
Apart from its direct effects on glucose entry, insulin also controls hepatic glucose production by 
suppressing hepatic glucose synthesis (gluconeogenesis) and stimulating glucose metabolism 
(glycolysis). This occurs through enhanced gene expression of glycolytic enzymes glucose 
kinase (GK), pyruvate kinase (PK) while decreasing expression of gluconeogenic enzymes 
glucose-6-phosphatase (G6Pase), fructose-1,6-biphosphatase (F-1,6-BPase) and 





1.1.3 Cellular insulin signaling 
Insulin binds to its receptor which is made up of 2 extracellular α-subunits and two trans-
membrane β-subunits with tyrosine kinase activity [22, 23]. Insulin binds to the α-subunit and 
activates the tyrosine kinase in the β-subunit which then auto-phosphorylates intracellular 
substrates such as the insulin receptor substrate (IRS), specifically isoform 1 (IRS-1) [24]. Upon 
phosphorylation, the IRS-1 protein interacts with a series of effector molecules containing Src 
homology 2 (SH2) domains that specifically recognize different phosphotyrosine motifs [22]. 
These include phosphatidylinositol-3-kinase (PI3K), made up of the p85 regulatory subunit and a 
p110 catalytic subunit whose activation occurs in response to interaction with the IRS-1 proteins 
[24, 25]. The activated PI3K catalyzes the change of phosphatidylinositol-4, 5-diphosphate 
(PIP2) into phosphatidylinositol-3,4,5-triphosphate (PIP3) [24]. PIP3 then activates proteins 
which contain a pleckstrin homology (PH) domain [22] such as the serine/threonine (Ser/Thr) 
phosphoinositide dependent protein kinase 1 (PDK1), which phosphorylates and activates 
several downstream kinases such as Akt/protein kinase B [26]. Akt is involved in stimulating the 
translocation of a glucose transporter-4 (GLUT-4) containing vesicles from the intracellular to 
the plasma membrane for glucose uptake [24]. Akt also stimulates the phosphorylation of a 
variety of proteins that affect cellular metabolism such as glucose kinase-3 (GSK3) [26], 
normally inactivated following phosphorylation. A key GSK3 substrate is glycogen synthase 
(GS), the rate limiting step in glycogenesis which catalyses the change of uridine di-phosphate 
glucose (UDP-glucose) to glycogen [27]. Phosphorylated GS is inactive [28] and this inhibits 
glycogenesis. Therefore, by Akt phosphorylating and inactivating GSK3 it promotes 
glycogenesis. Akt also phosphorylates and activates the Forkhead Box Protein O (FOXO) 




nuclear targets [24] thus reducing transcription activity. However, in low glucose levels, FOXO 
localizes in the nucleus and stimulates gluconeogenesis by promoting the expression of key 
gluconeogenic enzymes glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate 
carboxykinase (PEPCK) [29] (Figure 1.1). 
1.1.3.1 Insulin signaling defects in diabetes 
Insulin signaling defects have been implicated in the pathogenesis of DM. This is especially the 
case in type 2 DM although the exact mechanisms are still not well understood. Elevated fatty 
acids commonly seen in obesity are believed to play a key role. In obesity, adipocytes derived 
from pleuripotent mesenchymal stem cell precursors undergo low proliferation and 
differentiation leading to hypertrophic fat cells [30]. This activates the stress and inflammatory 
pathways [14, 16] which induces its endocrine functions by releasing adipocytokines (adipocyte-
secreted proteins) such as the tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), resistin 
aptly described by Housa et. al., [31], as "insulin resistance inducing factors". Studies have 
shown that TNF-α leads to loss of IRS-1 and GLUT-4 expression [32] while IL-6 impairs insulin 
signaling by decreasing activation of IRS-1 [33]. Resistin too has been implicated in impairing 
glucose tolerance and insulin action [34]. 
These hypertrophic adipocytes also have an enhanced lipolytic activity and a diminished capacity 
to take up FFAs resulting in an abnormal and ectopic intracellular deposition of fats in liver, 
skeletal muscle and the pancreatic beta cells [8, 14]. This overload leads to an increased 
intracellular accumulation of FFAs and its metabolites such as long chain fatty acid coenzyme A 
(LCFA-CoA), diacylglycerol (DAG) and ceramides [35-37]. The end result is activation of the 




receptor substrates (IRS) on serine residues [37] rather than on tyrosine ones eliciting different 
responses among the different insulin target tissues. In the skeletal muscle these serine-
phosphorylated forms cannot associate with and activate PI3K, resulting in decreased GLUT-4 
activity [35]. In the hepatic cells, it results in reduced insulin stimulation of GS activity and 
decreased phosphorylation of the FOXO transcription factor thus activating transcription of the 
rate-controlling enzymes of gluconeogenesis [24]. The end result is increased hepatic glucose 
production and decreased skeletal muscle glucose uptake, which contribute immensely to 




















1.1.4 Dyslipidemia in insulin deficiency 
DM is associated with a cluster of plasma lipid and lipoprotein abnormalities as a result of 
deficiency in insulin action and hyperglycemia. This is characterized by increased levels of very 
low density lipoproteins (VLDL), triglycerides (TG), reduced levels of HDL cholesterol [38]  
and a predominance of small-dense low density lipoprotein (LDL) [39]. This is especially the 
case in type 2 DM, a characteristic pattern referred to as diabetic dyslipidemia. However, 
elevated TG and decreased HDL levels have also been commonly observed in poorly controlled 
type 1 DM but usually resolves on insulin treatment [40]. Reduced insulin action results in an 
increased flux of FFA to the liver driving up the hepatic synthesis rates of VLDL and TG [41]. 
The secreted VLDL particles are metabolized to intermediate density lipoprotein (IDL) and 
further to LDL by lipoprotein lipase (LPL) which catalyses the rate-limiting step in lipoprotein 
metabolism [38, 41, 42]. Insulin deficiency diminishes the activity of LPL [43] and results in 
hypertriglyceridemia through a reduction in clearance of these lipoproteins. HDL is derived from 
metabolism of VLDL remnants and thus the reduced LPL activity causes a decrease in plasma 
HDL-cholesterol levels too [41, 43]. The rise in VLDL-TG promotes an abnormal exchange of 
TG and cholesteryl ester between VLDL, LDL and HDL, a process mediated by cholesterol ester 
transfer protein (CETP) [43]. As a result, ApoA-I easily dissociates from the TG-enriched HDL 
and is cleared rapidly from plasma thus reducing the availability of HDL [43]. These exchanges 
also result in increased small-dense LDL particles which readily undergo oxidative modifications 
promoting their uptake and retention in the vascular endothelium [44], a major risk factor for the 
development of cardiovascular complications. Regarded as a protective lipoprotein, HDL has 




main function is in reverse cholesterol transport where cells unload cholesterol for eventual 
excretion in the bile via the liver [43]. 
1.1.5 Complications of diabetes mellitus 
The escalating prevalence of DM is associated with an ever increasing burden of complications 
which are debilitating and even fatal. This situation is further compounded by delayed diagnosis 
which may increase the incidence and prevalence of diabetes thus exerting more pressure on the 
already stretched healthcare budgets and systems in the developing world. The complications of 
DM maybe acute or chronic.  
Acute complications develop within a short duration and are extremely fatal in absence of 
effective treatment. These include diabetic ketoacidosis (DKA) and non-ketotic hyperosmolar 
state [5, 45] and are the most common hyperglycemic emergencies. 
Chronic complications of DM result from changes in metabolism as a result of the 
hyperglycemic state. They are classified into macrovascular and microvascular complications. 
Progressively, they cause damage, dysfunction and ultimately failure of a number of organs. 
Macrovascular complications develop in the large arteries [42, 46] and manifest clinically as 
coronary artery disease (CAD) and stroke [46]. Microvascular complications occur as a result of 
damage to the microvasculature supplying the retinal, renal and neural tissues. This leads to 
diabetic retinopathy, nephropathy and neuropathy respectively. The diabetic foot syndrome, 
another complication arises from damage to both the micro and macro vasculature coupled with 





1.2 Background: Diabetic Ketoacidosis (DKA) 
Diabetic ketoacidosis (DKA) is a life threatening complication of diabetes mellitus. It is 
characterised by a triad of hyperglycemia, hyperketonemia and metabolic acidosis [48]. 
Hyperketonemia results from increased ketone body blood levels namely acetoacetate (AcAc),  
β-hydroxybutyrate (3HB) and acetone [48]. They serve as a major source of energy for tissues 
like the brain which are unable to utilize fatty acids [49, 50]. Ketone body levels are elevated in 
other conditions than DKA such as prolonged fasting and starvation [48, 49], prolonged exercise, 
consumption of a high fat diet and alcoholic intoxication [50]. It develops readily in pregnancy 
as a result of increased lipid energy metabolism [48] and also among neonates where they 
provide substrates for synthesis of cholesterol, fatty acids, and complex lipids like phospholipids 
and sphingolipids which are preferentially used over glucose as substrates for brain growth, 
myelination and lung phospholipids [51].  
1.2.1 Epidemiology of DKA 
Although commonly referred to as pathognomonic to type 1 DM, DKA might occur in type 2 
DM but only under conditions of catabolic stress such as trauma, surgery or infections [8, 52]. 
Prevalence is high among the economically poor diabetic patients [53, 54] while reportedly, 
women are prone to DKA compared to men although poor compliance to insulin treatment has 
been attributed to this [54]. Pregnant women with diabetes face a higher risk of DKA as 
pregnancy is a state of relative insulin resistance and accelerated starvation as glucose is readily 
absorbed across the placenta with resultant increase in lipolysis and ketogenesis [55].   
Mortality arising from DKA commonly occurs in children [54], teenagers and young adults with 
DM [52]. Among pregnant diabetic women, it is the leading cause of foetal loss as ketone bodies 




1.2.2 Precipitating factors of DKA 
The most frequent precipitating factor of DKA among diabetic patients includes infections and 
omissions or inadequate insulin doses [52, 56, 57]. Infection remains the most common risk 
factor of DKA [52, 56] with urinary tract infections and pneumonia among the most frequently 
encountered [58]. A  study by Mbugua et al. [59], identified infection and insulin omission as the 
most common precipitating factors. Other precipitating factors of DKA include myocardial 
infarction, cerebrovascular accidents, acute pancreatitis [56] alcohol abuse, pulmonary 
embolism, trauma [57] and use of medications such as steroids, thiazide diuretics and 
sympathomimetic agents [52] which affect carbohydrate metabolism.  
1.2.3 Pathophysiology of DKA 
Metabolic abnormalities in DKA occurs as a result of either absolute or relative insulin 
deficiency coupled with concomitant increases in the insulin plasma counter regulatory 
hormones, namely catecholamines, glucagon, cortisol and growth hormone. The catabolic nature 
of these hormones antagonises insulin’s anabolic activity in the liver, adipose and skeletal 
muscle. Cortisol increases proteolysis which increases production of amino acids (alanine and 
glutamine) and also muscle glycogenolysis which increases lactic acid production, which serve 
as substrates for gluconeogenesis [60]. Catecholamines, glucagon and cortisol also stimulate the 
gluconeogenic enzymes like PEPCK [60]. As a result, glucose production is enhanced eventually 
leading to marked hyperglycemia, a key feature of DKA. Lack of insulin also leads to 
phosphorylation and activation of hormone sensitive lipase (HSL) in the adipose tissue [58] 
which promotes lipolysis and releases FFA, the main substrates for ketogenesis into the liver.  
Hyperglycemia and increased ketone body production lead to osmotic diuresis with ketonuria 




hypoxia and hyperlactidemia (Figure 1.2). Oxidative stress and free radicals which may 
exacerbate β-cell dysfunction also lead to production of pro-inflammatory cytokines which 
further provoke the release of insulin counter-regulatory hormones [45]. 
 
Figure 1.2. Schematic diagram of the pathophysiology of diabetic ketoacidosis (DKA) [3]. 
1.2.3.1 Ketogenesis 
Glucagon, plays a key role in ketogenesis by influencing both gluconeogenesis and ketone body 
formation. Increase in glucagon levels as a result of insulin deficiency triggers the 
phosphorylation of the enzyme acetyl co-enzyme (CoA) carboxylase which catalyses the 




intermediate in the synthesis of long chain fatty acids inhibits fatty acid oxidation [57, 61] and 
facilitates FFA synthesis by inhibiting carnitine palmitoyl-O-transferase I (CPT I) [57, 58, 62]. 
CPT I is involved in transport of FFA across the mitochondrial membrane. Phosphorylation of 
acetyl CoA carboxylase reduces the production of malonyl CoA which leads to an elevation of 
CPT I levels and consequently, movement of FFA into mitochondria for oxidation and 
ketogenesis. Transport of FFA across the mitochondrial membrane occurs in the form of CoA 
after esterification to carnitine which is reversed by CPT II to form fatty acyl CoA which then 
enters the β-oxidative pathway (Figure 1.3). The acetyl CoA produced is used in the generation 
of AcAc and 3HB. 
 
 
Figure 1.3. The mitochondrial carnitine palmitoyl-O-transferase (CPT) system showing the steps 





After β-oxidation of fatty acids, acetyl CoA produced is the link to the TCA cycle. Normally,  
this channelling of acetyl CoA into the TCA cycle involves condensation with oxaloacetate [63]. 
However, under hypoglycemic conditions oxaloacetate is utilized preferentially in 
gluconeogenesis while the acetyl CoA is used in ketogenesis [63, 64] which   occurs through a 






Figure 1.4. The sequential steps of ketogenesis (HMG-CoA pathway) [65]. 
 
The enzyme β-ketothiolase (acetoacetyl-CoA thiolase)  catalyses the condensation of two acetyl 
molecules to form acetoacetyl CoA [63]. Acetoacetyl CoA is further condensed with another 
acetyl coA molecule forming hydroxyl methyl glutyryl CoA (HMG coA) in a reaction catalyzed 
by HMG CoA synthase [63, 65]. The HMG CoA formed is cleaved into AcAc and acetyl CoA 
by HMG CoA lyase [65]. AcAc is then reduced to 3HB by the enzyme 3HB dehydrogenase [63, 
65], a phosphatidyl choline dependent enzyme with reduced nicotinamide adenine dinucleotide 
(NADH) being oxidized to NAD [48]. The enzyme HMG-CoA synthase is the rate limiting step 
in the synthesis of ketone bodies [65] and is therefore involved in the control of ketogenesis. The 




relatively stable; however, acidosis in DKA leads to a reduced mitochondrial redox state which 
favors 3HB production [48, 50, 64, 66]. 
1.2.3.2 Ketolysis 
This is the process by which ketone bodies are converted to energy that can be used in tissue 
metabolism. It involves the reconstitution of acetoacetyl CoA from acetoacetate by the rate 
limiting enzyme, succinyl CoA-oxoacid transferase (SCOT) and subsequently, cleavage of an 
acetyl group from acetoacetyl CoA by the enzyme methyl acetoacetyl thiolase (MAT) to form 
acetyl CoA [48]. The acetyl CoA is then channeled into the TCA cycle. Although SCOT has 
been detected in a number of tissues, it is lacking in the liver [67]. And this makes the liver 
unable to utilize the ketone bodies but instead derives its energy from the degradation of amino 
acids [63]. However, MAT activity is highest in the liver with substantial amounts also found in 
the kidney, heart, adrenal glands and skeletal muscle [67].  
1.2.3.3 Acid-base balance in DKA 
Metabolic acidosis in DKA occurs as a result of the increased production of AcAc and 3HB 
coupled with decreased utilization by peripheral tissues such as the skeletal muscle. Dehydration, 
a key feature of DKA results in reduced glomerular filtration rate (GFR) and hence an increased 
retention of the ketone bodies further worsening the acidosis. AcAc and 3HB being strong 
organic anions dissociate freely leading to an increased hydrogen ion load which rapidly exceeds 
normal bicarbonate (HC0₃⁻) buffering capacity resulting in metabolic acidosis [52, 64]. The 
retention of these ketoanions eventually result in a high anion gap (AG) acidosis [68] as 






1.2.4 Management of DKA 
The true incidence of DM and by extension DKA in the developing world is largely unknown as 
the majority of patients remain undiagnosed. As a result, adequate management is still elusive. 
Therefore improvements in strategies on management or any of its related complication should 
aim to address this key issue.  
1.2.4.1 Clinical presentation of DKA 
Patient evaluation is critical in the management of DKA. It provides the necessary supportive 
information for preliminary diagnosis.  The symptoms characteristic of poorly controlled 
diabetes may be observed for a number days; however, metabolic alterations typical of DKA 
usually evolve within a short period of time usually <24 hours. These include a history of 
polyuria, polydipsia and weight loss, abdominal pain, vomiting and an altered mental state [45, 
56, 69]. Physical examination reveals Kussmaul (rapid and deep) breathing, a fruity acetone 
breath and features of dehydration [58, 69-71]. Particular attention should be paid to paediatric 
patients where presenting features of DKA may resemble other common illnesses such as 
bronchiolitis leading to misdiagnosis [54, 72]. This may delay treatment which worsens the 
prognosis as DKA progresses further to a more severe state.  
1.2.4.2 Diagnosis of DKA 
The initial laboratory evaluation of patients with suspected DKA includes determination of blood 
glucose, glycated haemoglobin, blood urea nitrogen/creatinine, serum and urine ketones, serum 
electrolytes with a calculated anion gap, serum osmolality, venous blood pH, complete blood 





Confirmatory laboratory diagnosis is based on a biochemical criteria characteristic of DKA. 
These include blood pH <7.3, serum bicarbonate concentration <15 mmol/L, blood glucose 
concentration >11 mmol/L with associated ketonemia and ketonuria [53, 73-75] and an increased 
anion gap (AG) [58, 76]. Based on these parameters, DKA has further been classified according 
to the severity (Table 1.2). 
Categories Venous blood pH Plasma bicarbonate (mM) 
Mild 7.2-7.3 15 
Moderate  7.1-7.2 10 
Severe ≤ 7.1 ≤ 5 
 
Table 1.2. Classification of DKA according to venous blood pH and plasma bicarbonate levels 
[3]. 
1.2.4.3 Treatment of patients with DKA  
The treatment of DKA is multifaceted and should involve a well-structured approach. Treatment 
guidelines currently in use are developed in the Western world and might miss out on certain 
aspects unique to the Third world and thus caution should be observed. The main goals in the 
treatment of DKA are adequate correction of dehydration, acidosis and electrolyte imbalances 
while avoiding treatment related complications. Appropriate drug therapy is instituted in 
infection related causes.  
1.2.4.3.1 Fluid replacement in DKA 
Fluid replacement in DKA is aimed at correcting the fluid and electrolyte deficits. Over the 
years, a number of fluid management protocols have been developed. Despite these, it is still a 




fundamental aspects in DKA treatment are still difficult to conclusively ascertain. Weight loss 
has been used as an indicator of dehydration [56, 72]. However, its main limitation is getting the 
accurate weight before the illness. Clinical presenting features too may be rendered unreliable. 
An example is hyperventilation in DKA due to metabolic acidosis which may lead to excessive 
drying of the oral mucosa resulting in over estimation of dehydration [77]. Biochemical variables 
too have been used to determine fluid losses. Hyperosmolality for example may preserve 
intravascular volume and thus maintain peripheral pulses, blood pressure and urine output until 
shock ensues [77] after severely underestimating dehydration. Currently, guidelines do not 
recommend clinical estimates of the volume deficits. Wolfsdorf et al., [72], cited them as 
inaccurate and subjective and recommended using 5–7% dehydration in moderate DKA and 10% 
dehydration in severe DKA. However, to optimize therapy, it is imperative that all these 
variables of dehydration be correlated with rigorous monitoring. 
Initial management involves rehydration to improve circulatory volume and tissue perfusion. 
This results in the restoration of extracellular fluid volume through administration of intravenous 
(IV) isotonic saline (0.9 % NaCl) [78, 79]. Normal saline is the fluid of choice [79, 80] and is 
also routinely used considering cost issues. Subsequent choice for fluid replacements is 
dependent on the state of dehydration, serum electrolyte levels and urinary output [56, 70]. 
Generally, if the corrected sodium levels are normal or elevated, hypotonic saline (0.45% NaCl) 
at a rate of 4-14 ml/kg/hr is administered [70, 81] which ensures a gradual correction of the fluid 
deficits as rapid correction is associated with a risk of cerebral oedema.  
1.2.4.3.2 Insulin treatment in DKA 
The discovery of insulin revolutionised the management of DKA. Prior to that, DKA was almost 




ketogenesis after which metabolism and renal excretion of the ketone bodies dissipates the 
acidosis. A key question always asked is; when is the right time to administer insulin? It is 
important that it be started after the patient has received initial fluid therapy because then, tissue 
perfusion will be restored and insulin distributed to all the target tissues. This should be about 1-
2 hours after the initial fluid expansion [72]. A study by Edge et al., [82], showed that early 
insulin administration, within the first hour was associated with an increased risk of cerebral 
edema. According to the study, the mechanism for this was related to the rapid changes in 
electrolytes which are greater during the initial phase of rapid rehydration when membrane 
electrolyte transport maybe most active.  
Potassium levels must always be obtained before insulin therapy is started. This is because 
administration of insulin increases cellular potassium uptake by stimulating cell membrane 
Na+/K+ ATPase [83] leading to decreased plasma levels. In hypokalemia (potassium levels < 3.3 
mmol/l) [56], potassium repletion should be initiated and insulin withheld as it worsens the 
hypokalemia which is life threatening as it may lead to cardiac arrhythmias [80, 84]. Insulin is 
also withheld in hypotensive patients with severe hypoglycaemia as it may lead to vascular 
collapse from the rapid decrease of blood glucose secondary to insulin administration which 
causes movement of fluid from extracellular to intracellular space [80]. Among these patients, 
stabilization of the blood pressure should be the main priority. 
Studies and guidelines on the management of DKA recommend the administration of low dose 
insulin via intravenous (IV) route as the most preferred route of delivery [53, 75, 85]. Compared 
to subcutaneous (SC) and intramuscular (IM) routes, IV administration has been shown to 
possess a shorter half-life thus easy to achieve accurate titration and a linear predictable fall in 




and SC routes compared to IV administration [87]. Over the years, studies have also shown that 
low dose insulin is effective in treatment of DKA by achieving a steady fall of plasma glucose 
levels while reducing risk of hypoglycaemia and hypokalemia [56, 88]. Another practise that still 
elicits debate is the use of a priming dose during insulin IV infusion. Some studies advocate for it 
[86] but concerns still exist over its clinical effectiveness. A number of recent studies have 
indicated that it confers no added advantage as long as continuous IV infusion is adequate [89, 
90] and may further potentiate the risk of undesirable effects such as hypokalemia and cerebral 
edema [72, 90]. The low dose continuous IV insulin infusion is administered at 0.1 U/kg/h) [56, 
80, 87]. Correction of hyperglycemia generally occurs faster than acidemia. Therefore, once 
plasma glucose reaches about 14 mmol/l, the insulin infusion rate is halved as 5% dextrose is 
added to the infusion fluid [56]. This avoids the complication of hypoglycemia until complete 
resolution of ketoacidosis. Thereafter, transition to SC insulin at 0.1 U/kg every 4 hours should 
be initiated at least 1-2 hours before IV infusion is stopped [91] because of the slow onset of 
action via SC route. The established DM patients can then resume their previous insulin doses 
with necessary adjustments while new dose regimens are worked out for the newly diagnosed. 
Despite continuous IV insulin administration being the most preferred route, SC and IM may still 
play a role in uncomplicated DKA and in resource poor settings where access to equipment such 
as infusion pumps is a challenge. Although tedious, administration of rapid-acting insulin 
analogs via SC and IM routes every 1-2 hours has been shown to be almost as effective as IV 
administration in resolution of hyperglycemia and ketoacidosis [72]. This then allows for 
treatment in the emergency departments, general wards and clinics especially in resource limited 
settings such as the developing world. This significantly reduces costs by eliminating need for 





1.2.4.3.3 Serum electrolyte levels in DKA 
Determination of serum potassium levels is a key laboratory test in DKA and must be performed 
on initial presentation, before commencement of treatment. Serum potassium levels may be 
normal, elevated or decreased, although total body deficits of about 3–6 mmol/kg are usually 
recorded among adults [53, 80]. Hyperglycemia causes extracellular hyperosmolality which 
causes water and potassium shifts into the extracellular space resulting in the normal or elevated 
levels which is further enhanced by insulin deficiency [92]. Insulin normally promotes shift of 
potassium into the intracellular space. However, deficits are still recorded. This is as a result of 
the hyperglycemia induced osmotic diuresis which enhances urinary losses [92]. 
Current treatment guidelines recommend that to prevent hypokalemia, replacement therapy 
should be initiated once levels fall below 5.5 mmol/l [93]. Above this, replacement should be 
withheld [80] as this may cause hyperkalemia which may cause cardiac arrest. During the 
replacement, it is recommended that potassium levels and the electrogram [ECG] be determined 
frequently [92, 94]. Adequate urine output should always be ensured [94] as this avoids 
hyperkalemia as a result of decreased renal excretion. It is therefore evident that initiation of 
potassium replacements with undetermined levels and compromised renal function may result in 
fatal outcomes. According to the clinical guidelines by De Beer et al. [93], administration of 40 
mmol/l of potassium is adequate when the serum levels are less than 3.3 mmol/l but when 
between 3.3 and 5.5 mmol/l, 20 to 40 mmol/l is appropriate. Potassium is given as an infusion 
mixture of phosphate and chloride [71] which avoids the risk of excess chloride administration.  
Phosphate levels are normal or elevated on initial presentation of DKA but are reduced by insulin 




[92] through increased urinary losses. However, concern about phosphate supplementation exists 
as the benefits are still unclear. Furthermore, excessive administration is associated with reported 
risk of hypocalcemia [58] with tetany, soft tissue calcification [92] hence caution is advised. 
Patients with serum phosphate levels <1 mg/dl experience tissue hypoxia  [94] due to a reduction 
of 2, 3-diphosphoglycerate (2, 3-DPG) in the red blood cells which increases affinity of 
haemoglobin to oxygen thus decreasing oxygen supply to tissues [52]. It is therefore 
recommended that such patients be nebulized. To correct these low levels, 20-30 mmol/l 
potassium phosphate is added to the infusion fluids and given over several hours [69].  However, 
excess phosphate administration should be avoided. 
1.2.4.3.4 Serum bicarbonate replacement in DKA 
Bicarbonate therapy in DKA is still controversial. Recent studies have not demonstrated any 
improvement on metabolic recovery on its administration [93, 95, 96]. Furthermore, its use is 
associated with serious life threatening adverse effects such as hypokalemia, paradoxical 
worsening of central nervous system acidosis [56, 69] and an increased risk of cerebral edema 
[89, 94]. Mostly, adequate hydration and insulin therapy automatically corrects the acidosis [91] 
hence no need for alkalinisation. Insulin inhibits ketogenesis and promotes ketoanion metabolism 
consuming protons along the way while regenerating bicarbonate and spontaneously correcting 
the acidosis [53, 92]. 
However, bicarbonate may be recommended in patients with severe metabolic acidosis (pH <7.0) 
[69] to whom 40 mmol/l is administered until the pH rises to 7.0 [94] although studies on this 
especially at the low pH are still lacking. Therefore, caution should be exercised as the rise in pH 




decreasing haemoglobin’s affinity [52]. This may cause tissue hypoxia and worsen the patient’s 
condition.  
1.2.5 Complications of DKA 
Cerebral edema is a serious and fatal complication of DKA. It is a rare condition [77] mostly 
prevalent among children and adolescents [97]. Reported incidences in both newly diagnosed 
and established cases are 0.7% in the United Kingdom [98], 2% in Australia [99] and 0.9% in 
Northern America [100]. However, in Africa; the true incidence is unknown as majority of the 
patients die undiagnosed. The pathogenesis is not clearly understood but accumulation of water 
in the brain tissue [101], in addition to breakdown of blood brain barrier, metabolic abnormalities 
or hyponatremia which are common in children under the age of 5 years  especially those with 
severe acidosis and hypocapnia [73]. 
Clinically, the presenting features include decreased level of consciousness and headache 
followed by seizures, sphincter incontinence, pupillary changes, papilledema, bradycardia and 
respiratory arrest [69]. Mortality is very high (>70%) [70] while chances of recovery without 
permanent disabilities are low [70, 73]. Therefore, measures to reduce the risk should be 
prioritized. These involve gradual correction of blood glucose levels, fluid and sodium deficits.  
Murcomycosis, an opportunistic fungal infection is a rare but fatal complication of chronic 
ketoacidosis, involving the respiratory tract and sinuses [102]. When disseminated it may further 
complicate cerebral edema in these patients [73]. 
Other serious complications of DKA include renal failure which although rare may necessitate 
dialysis, increased thromboembolic events known to occur in children following dehydration, 
central venous catheter placement in ICU or idiopathic elevation of von Willebrand factor [73]. 




treatment [73, 103]. Rhabdomyolysis commonly associated with renal failure may be 
experienced by paediatric patients with severe hyperglycemia, high osmolality and 
hypophosphatemia [73]. 
1.2.6. Limitations of the current treatment guidelines of DKA 
Major advances have been made in the management of DKA. However, despite these, high 
morbidity and mortality rates from DKA are still recorded. This is as a result of the numerous 
challenges experienced especially in the developing world. These include erratic supply of 
insulin, lack of proper storage facilities such as refrigerators. This is coupled with shortage of 
supplies such as syringes, infusion pumps and blood glucose measuring equipment due to poor 
healthcare systems. As a result, the economic cost of DM management has become unaffordable 
to the people as they are forced to acquire them individually.  
This is in addition to the side effects of insulin such  as allergic reactions like erythema, pruritus, 
indurations at the application site and lipoatrophy [104] which further compromise compliance, 
worsen glycemic control and complicate the disease process. As a result, the search for novel 
therapies which are safer, cheaper and therapeutically effective has been hastened shifting the 
focus of research to plants and plant products which have been used throughout human history to 
cure and prevent diabetes.  
1.3 Medicinal use of plants in diabetes 
Plants have been used as medicine since ancient times. It is believed that as early as the 
Neanderthal man, they had special healing powers [105, 106] with the earliest records of plant 
use as medicine found among Chinese [106], Egyptians and also in the code of Hammurabi  
[107]. They are particularly important in the developing world where traditional medical 




indicating that 80% of the world population is dependent on traditional medicine, 90% of which 
is derived from plants [108]. 
A lot of progress has been made concerning knowledge of bioactive components in plant foods 
and the role they play in health. Their consumption is no longer purely for their nutritive value 
but also as nutraceuticals which play an important role in the maintenance of health. These 
nutraceuticals include the polyphenols, phytoestrogens, phytosterols, phytates and 
polyunsaturated fatty acids [109]. The polyphenols, mainly found in fruits and vegetables are 
among the most important sources of bioactive components of the human diet [109]. Flavonoids, 
ubiquitously found in the plant kingdom are polyphenols and have been the subject of immense 
scientific interest. They are widely consumed for their biological and pharmacological properties 
such as antioxidant, anti-inflammatory, anti-allergic, antiviral, antibacterial, anti-mutagenic and 
anti-carcinogenic activities [110]. 
Studies have been done to demonstrate the antidiabetic effects of plants and thus justifying their 
use in traditional medicine. Among these plants include Vernonia amygdalina, Hypoxis 
hemerocallidea, Sclerocarya birrea, Psidium guajava, Sutherlandia frutescens [111] and Citrus 
paradisi [112] commonly known as the grapefruit. The grapefruit was first introduced as a 
weight loss food as part of the Hollywood diet of the 1930s, which recommended half of a fresh 
grapefruit before every meal for 12 days [113]. Recently, Fujioka et.al. [114], showed that 
grapefruit consumption leads to weight loss which is even more significant when it is consumed 
just before meals. This is believed to be due to its combined effects of low dietary energy density 
and high fibre content [115]. Based on these effects, the grapefruit and its constituents may 





1.3.1 The grapefruit 
Flavonoids constitute the most abundant bioactive constituent of the grapefruit, a popular 
worldwide fruit [116]. Commercially, the grapefruit is also of great importance in the juice 
industry and also as a source of essential oils and pectin [117]. However, claims of its medicinal 
properties have led to increased consumption and interest from researchers. Among the many 
reported medical uses include anti-diabetic [116], anti-atherosclerotic, anti-carcinogenetic [118] 
anti-inflammatory, anti-proliferative, and antimicrobial properties [119]. 
1.3.1.1 Phytochemistry of the grapefruit  
The grapefruit is rich in a large number of phytochemicals. These include the flavonoids, 
furanocoumarins (FC) [120, 121], limonoid aglycones, glucosides, ascorbic acid, folic acid, 
glucaric acid, carotenoids, pectin and potassium [116]. Flavonoids constitute the most abundant 
bioactive constituent of the grapefruit [116] and have a generic structure made up of 2 aromatic 
rings, A and B linked by a heterocyclic ring C as shown in figure 1.5. Based on changes on ring 
C, they are generally classified into six; flavonols, flavones, flavanones, anthocyanins, 
isoflavones and flavans as shown in figure 1.6. Flavanones are the most abundant making up 
98% of the total flavonoid content [122]. In grapefruit, flavonoids usually exist as glycosides 
where a sugar molecule is attached to the aglycone. Two types of glycosides are already 
classified; neohesperidosides and rutinosides [123]. Neohesperidosides (naringin, neohesperidin, 
poncirin and neoeriocitrin) consist of a flavanone with neohesperidose (rhamnosyl-α-1,2 
glucose) and have a bitter taste, while rutinosides (hesperidin, narirutin and didymin) have a 
flavanone and a rutinose (rhamnosyl-α-1,6 glucose) and are tasteless [123]. On ingestion, the 




120, 124]. Naringin, the glycoside of naringenin is the most abundant flavonoid in GFJ and is 
majorly responsible for its distinctive aroma and pungent taste [124]. 
The major furanocoumarins (FC) present in the grapefruit include bergamottin, 6’,7’-
dihydroxybergamottin (DHB) [125, 126]. These have been extensively studied as the causative 
agents of grapefruit-drug interactions. Grapefruit juice (GFJ) also contains FC dimers [125, 127] 
also known as spiroesters or paradisins which are present at lower concentrations than FC but 
have shown potent in vitro enzyme inhibitory activity [121]. Variations in the concentration of 
these flavonoids and FC in grapefruit have been reported. A number of factors have been cited as 
the cause among them the grapefruit variety, method of processing, storage conditions [121] and 











Figure 1.6. The six main classes of dietary flavonoids in citrus fruits [128]. 
1.3.1.2 Naringin and diabetes 
As the burden of obesity increases globally to epidemic proportions, strategies are being 
employed to try and curb it. In DM, the benefits of weight reduction are evident as its previously 
been shown that moderate weight loss among patients with type 2 DM was associated with 
improvements in glycemic control [129]. Further reports indicate that weight loss is also 
associated with improvements in insulin sensitivity, dyslipidemia and blood pressure [130]. The 
grapefruit is particularly associated with reduction of central/truncal obesity [113], a key 
characteristic of the metabolic syndrome and a major predisposing factor of type 2 DM. This has 
been attributed to its flavonoids such as naringin which not only improve abdominal obesity but 
other risk factors such as insulin resistance [131, 132], the main biochemical disturbance in 




Dietary flavonoids have been shown to possess anti-diabetic and anti-dyslipidemic activities with 
researchers currently trying to identify the exact roles played by these flavonoids. Naringin has 
been shown to possess anti-diabetic and anti-dyslipidemic activities [133]. 
These observations suggest that naringin improves glycemic control and might play a major role 
in treatment of DKA. As a result, this study proposed to investigate the effects of naringin 
consumption on DKA in type 1 diabetes rat model. 
 
1.4 AIM: To investigate the putative roles of naringin in the pathogenesis of diabetic 
ketoacidosis (DKA) in a diabetic rat model. 
  
1.4.1 Objectives  
1. To establish a type 1 diabetes rat model with diabetes ketoacidosis. 
2. To investigate the effects of naringin on diabetic ketoacidosis.  














2.0 Material and methods 
2.1 Chemical and reagents 
The chemicals and reagents used in the study were purchased from Sigma-Aldrich Pty. Ltd., 
Johannesburg, South Africa. Reagents and drugs used included naringin, D-glucose, 
streptozotocin, citrate and phosphate buffers, potassium chloride, sodium chloride, sulphuric 
acid, hydrochloric acid. 
Insulin (Novo Nordisk®, Norway), normal saline, portable glucometers and glucose test strips 
(Ascencia Elite™, Bayer Leverkusen, Germany) were purchased from a local pharmacy. 
Halothane and other accessories were provided by the Biomedical Research Unit (BRU) of the 
University of KwaZulu-Natal, Durban, South Africa. 
2.2 Study design 
2.2.1 Ethics approval 
The experimental protocol for the study was approved by the Animal Ethics Committee of the 








2.2.2 Animal treatment 
Male Spague-Dawley rats of 200-300g body weight were divided into 5 groups and housed 
seven rats per cage. Animals were given free access to standard commercial chow and drinking 
tap water ad libitum. The rats were maintained on a 12 hour dark-to-light cycle of 08.00 to 20.00 
hours light in an air controlled room (temperature 25 ±2ºC, humidity 55% ±5%) and were 
handled humanely, according to the guidelines of the Animal Ethics Committee of University of 
KwaZulu-Natal 
2.2.3 Induction of diabetes 
Diabetes was induced by intraperitoneal (IP) injection of 60 mg/kg body weight of streptozotocin 
(STZ) for type 1 diabetes. This was prepared by dissolving the STZ in 0.2 ml citrate buffer, pH 
4.5 and was administered after an overnight starvation of the rats. Three days after STZ 
administration, development of diabetes was confirmed by tail pricking to analyse the blood 
glucose levels. Rats with random blood glucose levels above 11 mmol/L were considered 
diabetic and were included in the study [134].  
2.2.4 Experimental design 
Type 1 DM was induced in group 3, 4 and 5. Groups 2 and 4 were orally treated with 50 mg/kg 
of naringin. Group 3 was treated with regular insulin (4 IU/kg) subcutaneously twice daily. 
Groups 1 and 5 were treated with 1 ml distilled water via gastric gavage. Insulin treatment was 
only initiated after the confirmation of the presence of diabetes.  Animal weights and water 
consumption were measured daily. On day 40, each animal was placed in metabolic cages and 
urine was collected over a 24 hour period, measured and recorded. On treatment day 42, 




puncture for plasma insulin, electrolytes and ketone body analysis while liver samples were 
excised, snap-frozen in liquid nitrogen and stored at -80˚C for further analysis. 
Group Diabetic status Treatment 
1 
Negative Distilled water 
2 Negative 50 mg/kg naringin 
3 Positive Regular insulin 
4 Positive 50mg/kg naringin 
5 Positive Distilled water  
 
                Table 2.1. Animal treatment schedule 
2.3 Methods 
2.3.1 Blood glucose testing 
Fasting blood glucose tests were done on treatment days 0, 14, 28 and 41 respectively whereas 
glucose tolerance test (GTT) was done on day 41. Blood glucose concentrations were determined 
after tail-pricking and were analysed by a portable glucometer. Prior to GTT, all animals were 
starved overnight. Fasting blood glucose (FBG) for GTT was then determined after intra 
peritoneal (IP) administration of 3.0 mg/kg body weight of glucose in normal saline. The blood 




groups. Area under the curve (AUC) was calculated from blood glucose time curves and 
presented as AUC units (mmol/L×minutes). 
2.3.2 Determination of plasma insulin 
An ultra-sensitive rat insulin enzyme-linked immunoassay kit (DRG Diagnostics, Marburg, 
Germany) was used to analyse the plasma insulin levels as per the manufacturer’s instructions. 
Briefly, 25 µl of samples/standards, 100 µl of enzyme conjugate were added to a 96-well plate 
and incubated on a plate shaker at 900 rpm for 2 hours at 25˚C. The plate was washed 6 times 
each with 700 µl of wash buffer after which 200 µl of substrate TMB was added into each well 
and incubated for 15 minutes at 25˚C. Stop solution (50 µl) was added to each well and 
incubated for 5 minutes on a plate shaker before measuring the optical density in a microplate 
reader (EZ Read 400, biochrom®) at 450 nm.  
2.3.3 Hepatic glycogen assay 
Hepatic glycogen content was measured by the modified method of Seifter et al., [135]. Briefly, 
the liver tissue was homogenised in 1.0 ml of 30% potassium hydroxide saturated with sodium 
sulphate. The homogenate obtained was dissolved by boiling in a water bath (100˚C) for 30 
minutes, vortexed and cooled in ice. Glycogen was then precipitated with 2.0 ml of 95% ethanol, 
vortexed, incubated in ice for 30 min and later centrifuged at 550 g for 30 min. The glycogen 
pellets obtained were then re-dissolved in 1 ml of distilled water which was thereafter treated 
with 1 ml of 5% phenol and 5 ml of 96-98% sulphuric acid respectively. This was incubated in 
ice bath for 30 min and the absorbance measured at 490 nm using a spectrophotometer (Genesys 





2.3.4 Determination of serum electrolyte and pH level 
Serum sodium (Na⁺), potassium (K⁺), chloride (Cl⁻), bicarbonate (HC0₃⁻) and blood pH levels 
were determined using an automated chemistry analyser (Beckman Coulter, Synchron LX20 
Clinical Systems, California, USA) while the pH was determined using a pH/ blood gas analyser 
(Chiron Diagnostics, Halstead, Essex, UK).  
The anion gap (AG) was calculated using the formula: 
𝐴𝐺 = {[𝑁𝑎+] + [K+]} − {[Cl−] + [HC03−] [68] 
2.3.5 Analysis of serum ketone body levels 
Serum and urine ketone body levels were determined using the spectrophotometric enzymatic 
assay kit (Enzychrom TM, BioAssay systems, EKBD-100) according to the manufacturer’s 
instructions. Briefly, 8 mM of acetoacetate (AcAc) standard was prepared by mixing 5 µl AcAc 
standard provided with 45 µl distilled water. 5 µl of the 8 mM AcAc standard and 5 µl distilled 
water were then transferred in separate wells of a clear flat bottomed 96 well plate.5 µl of each 
sample was also transferred into 2 wells, one sample well and one blank well. A working reagent 
for water, standard and sample wells was prepared by mixing 195 µl AcAc buffer, 8 µl AcAc 
reagent and 0.5 µl hydroxybutyrate dehydrogenase (HBDH) enzyme for each well. A blank 
reagent was also prepared by mixing for each blank well, 195 µl of AcAc buffer and 8 µl AcAc 
reagent (no enzyme). 195 µl of the working reagent was added to the water, standard and sample 
wells while 195 µl blank reagent was added to the sample blank wells with gentle tapping to 
ensure mixing. The solutions were then incubated at room temperature for 5 minutes and optical 
density (OD) read at 340 nm using a spectrophotometer (Genesys 20, Thermospectronic). The 





𝑂𝐷 𝑏𝑙𝑎𝑛𝑘 − 𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑤𝑎𝑡𝑒𝑟 − 𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 
A similar procedure was repeated for the 3-β hydroxybutyrate (3HB) assay using the 3HB buffer, 
3HB reagent and 3HB standard. The concentration was calculated as follows: 
[3𝐻𝐵] =
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒 – 𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − 𝑂𝐷 𝑤𝑎𝑡𝑒𝑟
 
 
2.4 Statistical significance 
The data was presented as mean ± SD and analyzed by GraphPad Prism Software Version 5.0. 
Mann–Whitney tests and/or Student t-tests were applied to the results to determine statistical 


















3.1 Animal growth change during treatment period 
The diabetic rat groups exhibited significant (p<0.0001) weight loss compared to the normal 
control group. In addition, diabetic rats treated with insulin and naringin exhibited significantly 
(p<0.0001) improved weight gain compared to the non-treated diabetic rat group. Treatment of 
the normal non diabetic rats with naringin had no significant change in weight gain in 


































































Figure 3.1. Animal weight changes during treatment period (***p<0.0001 compared to normal 






3.2 Water consumption during treatment period  
The average daily water consumption was consistently and significantly (p< 0.0001) higher in all 
diabetic rats compared to normal control group. However, water consumption was significantly 
(p<0.0001) reduced in the insulin and naringin treated groups compared to the diabetic control 




























































Figure 3.2. Water consumption during treatment period (***p<0.0001 compared to normal 









3.3 Urine output 
The urine output was significantly (p<0.0001) elevated among all the diabetic groups in 
comparison to the normal control rat group. Treatment of the diabetic group with insulin 
significantly (p<0.05) reduced the urine output as compared to the diabetic control group. 




































































Figure 3.3. 24-hour urine output (***p< 0.0001 compared to normal control, # p< 0.05 compared 








3.4 Blood glucose level measurements 
FBG levels were significantly higher (p<0.0001) in all diabetic rat groups compared to the 
normal non-diabetic control. However, compared to the diabetic control group no treatment 











































































Calculated AUCs showed that the diabetic groups (p<0.0001) significantly increased AUCs 
compared to normal control group confirming impaired glucose tolerance. However, compared 
to the diabetic control group, naringin and insulin treatment did not improve the AUCs among 




































































3.5 Fasting plasma insulin concentration 
Fasting plasma insulin concentration (FPI) were significantly (p<0.0001, p<0.01 and p<0.01) 
lower in the diabetic control, diabetic insulin and diabetic naringin compared with the normal 
control group. Treatment of the diabetic rats with insulin and naringin improved the plasma FPI 
levels although no significance was recorded compared to the diabetic control. Naringin 
treatment significantly (p=0.0003) elevated the plasma insulin levels among the non-diabetic rats 














































































3.6 Hepatic glycogen levels 
The diabetic control rat group had a significantly (p<0.0001) reduced hepatic glycogen content 
compared to the non-treated diabetic control group. Treatment of the diabetic rats with insulin 
and naringin showed significant (p<0.01 and p<0.05 respectively) increases in hepatic glycogen 
content as compared to the diabetic control group. Naringin treatment of normal rats showed 









































































Figure 3.6. Glycogen levels in hepatic tissue (***p< 0.0001, *p< 0.05 compared to normal 









3.7 Serum ketone body levels 
The 3HB levels were significantly (p<0.001) elevated in the diabetic control rat group compared 
to the normal control group. Insulin and naringin treatment significantly (p<0.001 and p<0.05 
respectively) reduced serum 3HB concentration in the diabetic groups compared to the diabetic 



































































Figure 3.7.A. Serum 3-β-hydroxybutyrate (3HB) levels (#p< 0.001 compared to normal control, 









Serum AcAc levels were significantly (p<0.0001) elevated in the diabetic rats compared to 
normal control rats. Naringin treatment significantly (p<0.05) reduced the blood AcAc levels in 

































































Figure 3.7.B. Serum acetoacetate (AcAc) levels (***p<0.0001 compared to normal untreated 











The total ketone body (TKB) levels was also significantly (p<0.0001) elevated in the diabetic 
control rats compared to the normal control rats. Treatment with insulin and naringin 
significantly (p<0.001 and p<0.001 respectively) decreased the TKB levels in diabetic groups 
































































Figure 3.7.C. Total ketone body levels in serum (**p<0.01 compared to the diabetic control 










The 3HB:AcAc ratio was significantly (p<0.05) elevated in the diabetic rat groups as compared 
to the normal rat control group. However, none of the treatment administered to the diabetic rat 







































































3.8 Serum electrolyte levels and anion gap (AG) 
Serum sodium, potassium and chloride levels did not exhibit any significant differences between 
the diabetic control and the normal control rat group.  Treatment of the diabetic rats with either 
naringin or insulin also had marginal effects on serum sodium, potassium and chloride ion levels. 
However, the bicarbonate level of the diabetic control group was significantly (p<0.0001) 
decreased compared to the normal control group. Treatment of the diabetic groups with insulin 
and naringin significantly (p<0.0001 and p<0.01 respectively) elevated the bicarbonate 














142.70±0.56 142.80±0.37 140.00±1.00 132.20±1.50 135.00±1.79 
Potassium 
6.42±0.30 7.120±0.59 5.87±0.12 7.34±0.59 7.56±0.46 
Chloride 
103.80±0.89 103.00±0.63 100.30±1.33 96.20±2.40 96.40±1.36 
Bicarbonate 
24.77±0.76 24.74±1.04 21.18±0.69 *** 17.63±0.64 ** 13.10±0.54 # 
 
Table 3.1. Serum electrolyte levels (***p< 0.0001, **p< 0.01 compared to the diabetic control 







The AG was significantly (p<0.0001) increased in the diabetic control rat group compared to the 
normal control group. Naringin and insulin treatment respectively, significantly (p<0.05) 




































































3.9 Blood pH levels 
The blood pH of the non-treated diabetic group was significantly (p<0.01) reduced compared to 
the normal control group. Treatment of the diabetic groups with naringin and insulin showed 
significant (p<0.01 and p< 0.05 respectively) increase in the blood pH compared to the diabetic 
control group (Table 3.2). 
Animal 
number 









8.5 7.5 8.5 8.5 6.0 
2 
8.5 9.0 8.0 7.0 6.5 
3 
7.5 8.0 7.5 7.5 7.0 
4 
8.5 8.0 8.5 8.5 7.0 
5 
8.5 8.0 8.0 9.0 6.5 
6 
7.0 7.5 7.5 8.5 5.5 
7 
7.5 7.5 7.5 7.0 8.0 
Mean 
8.00±0.24 7.93±0.20 7.93±0.17* 8.00±0.31** 6.64±0.30# 
 
Table 3.2. Blood pH levels (**p< 0.01, *p< 0.05 compared to the diabetic control group, #p< 










This study investigated the effects of naringin on blood glucose and ketone body homeostasis in 
DKA in type 1 diabetic Sprague-Dawley rats. The results indicate that naringin does not exert 
any blood glucose lowering effects in non-diabetic and STZ-induced type 1 diabetic rats. This 
validates our previous study that naringin does not have blood glucose lowering effects in type 1 
diabetes [136]. The results also suggest that naringin treatment does not improve polyuria, 
AUCs, serum 3HB:AcAc ratio in diabetic rats. However, naringin reversed weight loss, 
increased hepatic glycogen, decreased serum 3HB, AcAc, TKB and bicarbonate concentrations 
and improved blood pH and AG in diabetic rats. This suggests that naringin may play a major 
role in management of DKA.  
4.2 Effects of naringin on glucose homeostasis 
The diabetic animals used in the study were type 1 diabetic rats with absolute lack of insulin. 
This was achieved by destroying the pancreatic β-islet cells using STZ, 60 mg/kg body weight. 
STZ is a glucosamine nitrosourea compound derived from Streptomyces achromogenes and used 
as a chemotherapeutic agent in the treatment of cancer [137]. It selectively destroys the 
pancreatic β-islet cells. This selectivity has been attributed to the glucose moiety in its structure 
which enables it to enter the pancreatic β-islet cells using the GLUT-2 glucose transporter [138]. 
Toxicity to the β-islet cells by STZ occurs as a result of alkylation and damage to the 
deoxyribonucleic acid (DNA), depleting NAD+ which in turn inhibits insulin secretion and 




damage to DNA through oxidative stress by liberating nitric oxide group from its nitroso moiety 
[138] which causes the oxidative damage. 
The effects of STZ observed in our study included elevation of blood glucose levels, polydipsia, 
polyuria, weight loss, and hyperketonemia among the STZ-induced diabetic control rats 
indicating lack of insulin secretion. However, treatment of the normal and diabetic rats with 
naringin improved the fasting plasma insulin levels suggesting that naringin preserved residual 
pancreatic β-cell function or induced regeneration of the cells damaged by STZ in the diabetic 
rats. Weight loss was significantly (p<0.0001) elevated in all the diabetic rat groups compared to 
the normal control rats (Figure 3.1). This is attributed to lack of insulin, an anabolic hormone 
whose deficiency leads to muscle protein breakdown and decreased synthesis [139]. 
Furthermore, insulin deficiency is coupled with concomitant increases in insulin counter 
regulatory hormones namely catecholamines, glucagon, cortisol and growth hormone [58].  
These hormones are catabolic in nature and thus contribute to more weight loss. Treatment of the 
diabetic rats with insulin significantly (p<0.0001), (Figure 3.1) improved weight loss suggesting 
as expected that insulin exerted anabolic metabolic effects. Naringin also significantly 
(p<0.0001), (Figure 3.1) reversed the weight loss. This shows that like insulin, naringin may also 
be inhibiting lipid and protein catabolism associated with insulin deficiency since naringin 
treatment on normal non-diabetic rats did not have any significant effect on weight change. This 
further suggests that naringin does not have any effect on the animal’s natural growth.  
Polidypsia and polyuria was also observed among the diabetic animals. This was shown by an 
increased average daily intake of water and urine production respectively that was significantly 
(p<0.0001), (Figure 3.2 and 3.3 respectively) higher in the diabetic groups compared to the 




draws fluid from the intracellular compartment which is then lost through the kidney (diuresis) 
and may lead to dehydration. As a compensatory mechanism, increased osmolality results in 
hypothalamic osmoreceptors activating release of a neurohormone, antidiuretic hormone which 
attempts to correct the hyperosmolar state by acting on the kidneys to conserve water [140] thus 
decreasing urine output. Failure of this mechanism leads to activation of thirst [140] which leads 
to the increased water intake. Insulin treatment on the diabetic rats reversed both polyuria and 
polydipsia. However, naringin treatment on the diabetic rats reversed only polydipsia and had no 
effect on polyuria. This suggests that naringin inhibited thirst activation but had no anti-diuretic 
effect in the diabetic state considering the fact that naringin treatment on normal non-diabetic 
rats did not exhibit any change in urine production when compared to the normal non-treated 
rats.  
Insulin deficiency is associated with increased hepatic gluconeogenesis, decreased glucose 
utilization, enhanced glycolysis and reduced glycogen synthesis. All these result in 
hyperglycemia, a key feature characteristic of diabetes. In the study, FBG concentrations were 
significantly (p<0.0001), (Figure 3.4.A) elevated in all the diabetic rat groups compared to the 
normal control. In addition, calculated AUCs showed that the diabetic groups had significantly 
(p<0.0001), (Figure 3.4.B) increased AUCs compared to the normal control group confirming 
impairment of glucose tolerance. Surprisingly however, insulin treatment did not improve FBG 
concentration and AUC compared to the non-treated diabetic rats. Treatment of the diabetic rats 
with naringin too did not show any significant reduction in blood glucose levels compared to the 
diabetic control rat group. These observations further support results from a previous study in 
our laboratory [136] that naringin does not ameliorate hyperglycemia in diabetic type 1 rats. This 




aglycone naringenin [133, 141, 142]. The studies [133, 141] reported that naringin acts by 
suppressing hepatic expression of key gluconeogenic enzymes such as PEPCK and G6Pase. 
However, majority of these studies have been done in type 2 diabetic animals or diet modified 
set up. This suggests that naringin exerts metformin-like effects and might require insulin for it 
to exhibit hypoglycemic effects in diabetes. Metformin, a bi-guanide drug acts by activation of 
the energy-regulating enzyme, AMP-activated protein kinase (AMPK), to achieve its glycemic 
control in type 2 DM [143]. 
The non-treated diabetic rats had significantly (p<0.0001), (Figure 3.6) reduced glycogen levels 
compared to the normal control. This as expected is due to insulin deficiency as insulin improves 
glycogen storage by increasing expression of glycogen synthase (GS), the rate limiting step in 
glycogen synthesis [27]. The diabetic groups treated with insulin and naringin significantly 
(p<0.05) (Figure 3.6) increased the hepatic glycogen levels respectively as compared to the non-
treated diabetic group. This further supports previous studies which have shown that naringin 
improves glycogen storage [140, 141], although the studies are conducted in a different 
metabolic set-up from our study. 
4.3 Effects of naringin on ketone body concentration and acid base balance 
The levels of 3HB, AcAc and TKB were significantly (p<0.0001), (Figures 3.7.A, 3.7.B and 
3.7.C respectively) elevated in the diabetic non-treated rat groups as compared to the normal 
control group showing evidence of ketogenesis. This is expected as a consequence of insulin 
deficiency which normally inhibits the activity of the enzyme HMGCoA synthase, the rate 
limiting step in ketogenesis [63]. However, surprisingly, marginal effect was observed on AcAc 




be acting by inhibiting HMGCoA synthase activity as evidenced by decreased serum TKB, 
AcAc and 3HB levels in comparison to the non-treated diabetic rats. A previous study by Jung et 
al. [133] further showed that naringin reduces the levels of CPT. CPT is involved in the transport 
of FFA across the mitochondrial membrane into  mitochondria for β-oxidation and ketogenesis 
[61].  Therefore, with reduced CPT levels, there is reduced ketogenesis due to decreased supply 
of FFA. The ratio of 3HB:AcAc generally reflects the mitochondrial redox state and normally it 
is usually relatively stable. However, in DKA, there is a reduced mitochondrial redox state which 
favours 3HB production [50, 63, 64]. This is supported by the results in this study which show a 
significant (p<0.05), (Figure 3.7.D) increase in the ratio among the diabetic rat groups in 
comparison to the normal control rats. However, treatment with insulin and naringin did not 
result in any significant improvements in the ratio. The results of the study therefore show that 
naringin did not cause any shift towards a more reduced state which is more surprising despite its 
known antioxidant activity. 
Increased ketogenesis observed in diabetes is associated with overproduction and accumulation 
of ketone bodies (AcAc and 3HB) which are strong organic anions. These dissociate freely 
producing a large amount of hydrogen ions which bind and overwhelm the serum bicarbonate 
buffering capacity eventually leading to acidosis. This is shown by the decreased bicarbonate 
concentration and decreased pH among the diabetic animals. However, treatment of the diabetic 
rats with naringin improved bicarbonate and pH levels significantly (p<0.05 and p<0.01 
respectively), (Table 3.1 and 3.2 respectively) compared to the diabetic control group. Further 
evidence of an acid base disorder in DKA is seen by the significant (p<0.05), (Figure 3.8) 
increase in AG among the diabetic control group compared to the normal control group. The 




by naringin as well as insulin treatment among the diabetic rats with significant (p<0.01), (Figure 
3.8) improvements observed compared to the diabetic control. These results show that naringin 
reverses ketogenesis among the diabetic rats. It is also important to note that naringin did not 
have any significant effects on the ketone body levels in normal rats. 
 4.4 Conclusion 
In this study, Sprague-Dawley rats with type 1 DM showed important biochemical markers for 
DKA including hyperglycemia, ketonemia, metabolic acidosis, decreased bicarbonate levels 
coupled with an increased AG which were corrected upon treatment with naringin. The results 
from this study therefore indicate that naringin as a nutritional supplement could have a 
protective role against ketoacidosis in type 1 diabetes and might also play a major role as an 
adjunct therapy in management of patients with DKA but only after conduction of clinical 
studies. This could be of enormous clinical and economic significance considering the 
morbidities and mortalities recorded as a result of complications caused by DKA. 
Naringin treatment did not improve glucose intolerance in type 1 diabetes. It is therefore likely 
that it may have been as a result of insulin deficiency. It is therefore suggested that naringin may 
possess metformin like activity which require insulin to be able exert its anti-hyperglycemic 
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